These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC: 10702-001
Introduction
The pharmaceutical market is complex and influenced by various factors, including regulatory changes, competition from generics and biosimilars, and global economic trends. This analysis will focus on the market dynamics and price projections for the drug identified by the NDC code 10702-001, which corresponds to Lomaira, a prescription drug manufactured by KVK-Tech, Inc.
Current Market Trends
Prescription Drug Pricing
Prescription drug pricing is a highly dynamic and often opaque field. The prices of drugs are typically based on the Average Wholesale Price (AWP) minus discounts negotiated by Pharmacy Benefit Managers (PBMs)[2].
Average Wholesale Price (AWP): AWP has consistently increased over the years, with 84.1% of AWP changes resulting in price increases since 2000. However, the National Average Drug Acquisition Cost (NADAC) is seen as a more accurate reflection of retail pharmacy costs and has decreased by as much as 44% over a five-year period for generics[2].
Generic and Brand Drug Pricing
Generic Drugs: The analysis by the Maine Health Data Organization (MHDO) shows that the Wholesale Acquisition Cost (WAC) for generic drugs generally decreased in 2021, with an average percent decrease of -49.40% for those drugs that saw price changes. This trend indicates that generic drugs are becoming more affordable[1].
Brand Drugs: In contrast, the WAC for brand drugs has increased, with most categories seeing rises similar to previous years. This increase is a concern for many, as it contributes to higher healthcare costs[1].
Specifics of Lomaira (NDC: 10702-001)
Product Overview
Lomaira is a prescription drug used for weight management and is available in tablet form. It is manufactured by KVK-Tech, Inc.[5].
Pricing Dynamics
Wholesale Acquisition Cost (WAC): The WAC for Lomaira would need to be compared against other drugs in its class to understand its pricing dynamics. Given the trend of decreasing WAC for generic drugs, if Lomaira has a generic equivalent, it is likely that the prices would be lower compared to brand-name counterparts[1].
Discounts and Rebates: The actual cost to payers can be significantly lower due to discounts and rebates negotiated by PBMs. For example, the MHDO analysis showed that the cost to payers for generic drugs was significantly lower than for brand-name drugs, with an average net cost reduction of 50.93% when generic products were dispensed[1].
Regulatory and Market Factors
Regulatory Changes
Inflation Reduction Act: This act has significant implications for the pharmaceutical industry, particularly in the United States. It aims to control drug prices and could impact the pricing strategy for drugs like Lomaira[3].
Global Regulatory Changes: Changes in regulations, especially in Europe, and geopolitical uncertainties can also affect drug pricing and availability. Companies are preparing for these changes, which could influence market dynamics[3].
Competition from Generics and Biosimilars
Generic Competition: The entry of generic versions of drugs can significantly reduce prices. For instance, the MHDO report noted that generic NDCs were priced lower than brand equivalents, with an average year-end generic discount from brand WAC of 62.26%[1].
Biosimilars: While Lomaira is not a biologic, the trend of increasing biosimilar competition in the market can influence overall pricing strategies for pharmaceutical companies[3].
Price Projections
Short-Term Projections
Given the current trends, if Lomaira has a generic equivalent, it is likely that the prices will decrease. The MHDO data suggests that generic drugs have seen significant price reductions, which could apply to Lomaira if it faces generic competition[1].
Long-Term Projections
Regulatory Impact: The Inflation Reduction Act and other regulatory changes could lead to more controlled price increases or even reductions in the long term. This would be beneficial for consumers but could impact the revenue of pharmaceutical companies[3].
Market Competition: As more generics and biosimilars enter the market, the pricing pressure on brand-name drugs will increase. This competition is likely to drive prices down over the long term[3].
Key Takeaways
Pricing Trends: Generic drugs are seeing significant price reductions, while brand drugs continue to experience price increases.
Regulatory Impact: Regulatory changes, such as the Inflation Reduction Act, are likely to influence drug pricing.
Market Competition: Increased competition from generics and biosimilars will continue to drive prices down.
Actual Costs: Discounts and rebates can significantly reduce the actual cost to payers.
FAQs
What is the current trend in prescription drug pricing?
Prescription drug pricing is complex, with AWP consistently increasing, but NADAC prices for generics have been decreasing.
How do generic drugs impact the pricing of brand-name drugs?
Generic drugs are generally priced lower than brand-name drugs, with an average year-end generic discount from brand WAC of 62.26%[1].
What is the impact of the Inflation Reduction Act on drug pricing?
The Inflation Reduction Act aims to control drug prices, which could lead to more controlled price increases or reductions in the long term[3].
How do regulatory changes affect the pharmaceutical market?
Regulatory changes can influence pricing strategies, availability, and the overall market dynamics of pharmaceuticals[3].
What role do PBMs play in drug pricing?
PBMs negotiate discounts and rebates, which can significantly reduce the actual cost to payers for prescription drugs[2].
Sources
MHDO Rx Transparency Report - Maine Health Data Organization
Spotlight on Prescription Drug Pricing in Q1 2024 Trends - Segal
2025 Life Sciences Executive Outlook - Deloitte Insights
International Market Size and Prices - ASPE
NDC Package 10702-001-09 Lomaira Tablet Oral - NDC List
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.